As the clinical research industry continues its digital evolution, site management organizations face mounting pressure to modernize their operations while maintaining the highest standards of data quality and regulatory compliance. The traditional paper-based systems that have long dominated clinical trials are giving way to sophisticated electronic solutions that promise greater efficiency, accuracy, and quality.
Panthera, the UK’s largest site management organization (SMO), has embarked on an ambitious digital modernization journey. After carefully evaluating the clinical research technology landscape, Panthera recently selected CRIO as their technology partner, implementing a fully integrated suite of solutions including Clinical Trial Management System (CTMS), eSource, eConsent, and eRegulatory capabilities.
With their CTMS and eConsent implementations successfully completed, Panthera now stands poised to launch their first study utilizing eSource technology – a milestone that represents not just a technological upgrade, but a fundamental shift in how clinical data is captured, managed, and leveraged throughout the research process.
In this interview, Stuart Young, Chief Executive Officer, and Andy Broomhead, Chief Information Officer at Panthera Clinical Research, provide insights into their digital transformation journey. They discuss the strategic drivers behind their decision to transition to eSource, reveal the methodical approach they took to evaluate and select the right technology partner, and share their expectations for how this implementation will revolutionize their site operations.
- What prompted your decision to transition from paper-based source documentation to eSource technology?
At Panthera, we recognised that our scale and operational complexity were increasingly constrained by traditional paper-based source documentation. With six active sites and a growing national footprint, the inefficiencies of manual processes were becoming a barrier to optimal operational performance. Our decision to move to eSource was rooted in our broader digital strategy: to build a unified, modern clinical infrastructure that aligns with both sponsor expectations and internal operational goals. A key driver was the need for real-time access to high-quality data across all sites, something only a fully digital environment could offer. We also wanted to ensure our business intelligence (BI) and reporting capabilities remained best-in-class. By integrating CRIO eSource with BigQuery, we gain full access to structured, queryable source data across our studies. This enables granular visibility, rapid performance tracking, and study-level insights — all of which support agile, evidence-led decision making. We saw eSource not as a remedy to any problem, but as a strategic evolution of how clinical data should be captured and utilised. It reflects our broader objective of embedding digital transformation across the entire patient and data lifecycle.
- Can you walk us through your technology evaluation process? What criteria were most important to Panthera during the selection?
Our technology evaluation process was multi-disciplinary from the outset. Input from all departments was key. We engaged clinical operations, quality assurance, IT, and site staff to ensure the solution we selected would meet both compliance requirements and the practical needs of end users. Key priorities included full compliance with regulatory standards like 21 CFR Part 11 and MHRA expectations and an intuitive user interface that would reduce the learning curve for our research staff. CRIO stood out due to its unified architecture, combining CTMS, eSource, eConsent, and regulatory tools within a single platform along with its capacity to support direct data access via BigQuery, which was non-negotiable for us. Before finalising our decision, we tested shortlisted platforms in sandbox environments with live site staff to get direct feedback on usability, flexibility, and workflow compatibility.
- Do sponsor feasibility questionnaires often inquire about your electronic source or remote monitoring capabilities? In your view, does being an eSource-enabled site give you a competitive edge in site selection?
Yes, sponsors are increasingly focusing on digital capabilities during feasibility. Questions around eSource, remote monitoring access, and source-to-EDC workflows are becoming the norm. Being able to demonstrate eSource capability has become more than a nice-to-have; it’s rapidly becoming a prerequisite, particularly in high-throughput trial models. Sponsors value sites where data is available in real time and where visibility doesn’t depend on physical monitoring visits. Our eSource setup, combined with robust analytics infrastructure positions us well to meet these expectations and operate as a scalable, high-performing research partner.
- What impact do you anticipate eSource will have on your site operations and staff workflows?
The shift to eSource is expected to streamline many aspects of our site operations. We expect eSource to simplify site workflows, not complicate them. One of the most valuable aspects is standardisation — procedures and visit documentation can be pre-configured in accordance with protocol, reducing the likelihood of variation or omission. Staff benefit from clear task sequences and smart data fields that support protocol fidelity. It also enhances our ability to manage studies centrally: our Operations and QA teams will have real-time access to in-progress documentation, enabling earlier support and better oversight. Most importantly, it aligns with the way modern research is delivered — digitally, collaboratively, and with data accessibility at its core
- In what ways does eSource-based data capture support protocol compliance and improve data quality?
eSource brings structure and precision to clinical documentation in a way that’s difficult to replicate on paper. With mandatory fields, logic-based prompts, and real-time validation, we’re able to reduce missing or inconsistent data at the point of entry. It helps enforce protocol-specific parameters, such as visit windows or eligibility thresholds, with automated alerts when deviations are at risk. The use of standardised visit templates across sites also brings consistency to documentation and reduces variability across study teams. Perhaps most importantly, eSource provides full traceability and auditability, ensuring every entry, change, and review is logged. This level of transparency strengthens our compliance posture and gives both sponsors and auditors greater confidence in our data.
- How do you see eSource technology evolving over the next few years?
We expect eSource to evolve rapidly in both capability and connectivity. Increasingly, sponsors are looking for direct data pipelines between site systems and EDC platforms, and we see a future where API-driven integration becomes the norm. There is also huge potential for AI-assisted documentation; for example, suggesting values or auto-completing based on past visits, which could reduce manual burden on site staff even further. Over time, we believe regulatory expectations will also evolve to formalise best practices in digital source, including standardised audit trails and validation standards. For Panthera, being at the forefront of this movement is not only a technical imperative but a competitive one.